Published in J Clin Invest on February 01, 1994
A cytomegalovirus-encoded mitochondria-localized inhibitor of apoptosis structurally unrelated to Bcl-2. Proc Natl Acad Sci U S A (1999) 3.22
Interaction of the 72-kilodalton human cytomegalovirus IE1 gene product with E2F1 coincides with E2F-dependent activation of dihydrofolate reductase transcription. J Virol (1995) 1.59
CCAAT box-dependent activation of the TATA-less human DNA polymerase alpha promoter by the human cytomegalovirus 72-kilodalton major immediate-early protein. J Virol (1995) 1.47
CREB and CREB-binding proteins play an important role in the IE2 86-kilodalton protein-mediated transactivation of the human cytomegalovirus 2.2-kilobase RNA promoter. J Virol (1996) 1.43
Upregulation of tumor necrosis factor-alpha gene by Epstein-Barr virus and activation of macrophages in Epstein-Barr virus-infected T cells in the pathogenesis of hemophagocytic syndrome. J Clin Invest (1997) 1.41
Anti-human cytomegalovirus activity of cytokines produced by CD4+ T-cell clones specifically activated by IE1 peptides in vitro. J Virol (1996) 1.40
Human cytomegalovirus infection inhibits tumor necrosis factor alpha (TNF-alpha) signaling by targeting the 55-kilodalton TNF-alpha receptor. J Virol (2003) 1.28
Human cytomegalovirus immediate-early 2 (IE2) protein can transactivate the human hsp70 promoter by alleviation of Dr1-mediated repression. J Virol (1996) 1.06
Induction of susceptibility to tumor necrosis factor by E1A is dependent on binding to either p300 or p105-Rb and induction of DNA synthesis. J Virol (1996) 1.02
Latent Kaposi's sarcoma-associated herpesvirus infection of monocytes downregulates expression of adaptive immune response costimulatory receptors and proinflammatory cytokines. J Virol (2012) 0.95
Possible role of human cytomegalovirus in pouchitis after proctocolectomy with ileal pouch-anal anastomosis in patients with ulcerative colitis. World J Gastroenterol (2007) 0.89
Herpesvirus Infections and Childhood Arterial Ischemic Stroke: Results of the VIPS Study. Circulation (2016) 0.88
Dendritic cell biology in human cytomegalovirus infection and the clinical consequences for host immunity and pathology. Virulence (2012) 0.84
The human cytomegalovirus UL26 protein antagonizes NF-κB activation. J Virol (2014) 0.83
Cytomegalovirus colitis in a patient with Behcet's disease receiving tumor necrosis factor alpha inhibitory treatment. World J Gastroenterol (2008) 0.82
Multiple Transcripts Encode Full-Length Human Cytomegalovirus IE1 and IE2 Proteins during Lytic Infection. J Virol (2016) 0.76
Replication of CMV in the gut of HIV-infected individuals and epithelial barrier dysfunction. PLoS Pathog (2017) 0.75
Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry (1979) 180.95
Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol Cell Biol (1982) 116.75
RNA molecular weight determinations by gel electrophoresis under denaturing conditions, a critical reexamination. Biochemistry (1977) 38.82
Shock and tissue injury induced by recombinant human cachectin. Science (1986) 16.24
Immunoglobulin gene transcription is activated by downstream sequence elements. Cell (1983) 15.53
Identification of a common nucleotide sequence in the 3'-untranslated region of mRNA molecules specifying inflammatory mediators. Proc Natl Acad Sci U S A (1986) 15.20
Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature (1988) 13.42
Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature (1986) 11.09
Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature (1985) 7.22
Tumor necrosis, cachexia, shock, and inflammation: a common mediator. Annu Rev Biochem (1988) 5.75
Activation of the major immediate early gene of human cytomegalovirus by cis-acting elements in the promoter-regulatory sequence and by virus-specific trans-acting components. J Virol (1985) 5.47
Regulation of tumor necrosis factor alpha transcription in macrophages: involvement of four kappa B-like motifs and of constitutive and inducible forms of NF-kappa B. Mol Cell Biol (1990) 5.08
trans-activation and autoregulation of gene expression by the immediate-early region 2 gene products of human cytomegalovirus. J Virol (1988) 4.69
Identification and characterization of the human cytomegalovirus immediate-early region 2 gene that stimulates gene expression from an inducible promoter. J Virol (1987) 4.33
Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. J Exp Med (1988) 4.02
Transactivation of a human cytomegalovirus early promoter by gene products from the immediate-early gene IE2 and augmentation by IE1: mutational analysis of the viral proteins. J Virol (1990) 4.01
Immediate-early gene region of human cytomegalovirus trans-activates the promoter of human immunodeficiency virus. Proc Natl Acad Sci U S A (1987) 3.82
Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Clinical findings, diagnosis, and treatment. Ann Intern Med (1988) 3.49
Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis (1986) 3.31
Autoregulation of the human cytomegalovirus major immediate-early gene. J Virol (1985) 2.91
Human tumor necrosis factor alpha gene regulation by virus and lipopolysaccharide. Proc Natl Acad Sci U S A (1990) 2.63
Interleukin-1 and tumor necrosis factor alpha can be induced from mononuclear phagocytes by human immunodeficiency virus type 1 binding to the CD4 receptor. J Virol (1989) 2.42
Cytomegalovirus infection in patients with AIDS. J Infect Dis (1988) 2.35
Cytomegalovirus infection in the normal host. Medicine (Baltimore) (1985) 2.34
Cytokine (tumor necrosis factor, IL-6, and IL-8) production by respiratory syncytial virus-infected human alveolar macrophages. J Immunol (1991) 2.27
Participation of two human cytomegalovirus immediate early gene regions in transcriptional activation of adenovirus promoters. Virology (1987) 2.26
Enhancers and transcription factors controlling the inducibility of the tumor necrosis factor-alpha promoter in primary macrophages. J Immunol (1991) 1.90
The 72K IE1 and 80K IE2 proteins of human cytomegalovirus independently trans-activate the c-fos, c-myc and hsp70 promoters via basal promoter elements. J Gen Virol (1992) 1.79
Role of tumor necrosis factor-alpha in lipopolysaccharide-induced pathologic alterations. Am J Pathol (1990) 1.66
Genetic analysis of the human tumor necrosis factor alpha/cachectin promoter region in a macrophage cell line. J Exp Med (1989) 1.62
A CAT reporter construct allows ultrasensitive estimation of TNF synthesis, and suggests that the TNF gene has been silenced in non-macrophage cell lines. J Clin Invest (1991) 1.48
Modulation of interleukin 1 beta gene expression by the immediate early genes of human cytomegalovirus. J Clin Invest (1990) 1.46
Cytomegalovirus induction of tumor necrosis factor-alpha by human monocytes and mucosal macrophages. J Clin Invest (1992) 1.24
Primary cytomegalovirus and opportunistic infections. Incidence in renal transplant recipients. JAMA (1978) 1.24
The functional importance of a cap site-proximal region of the human prointerleukin 1 beta gene is defined by viral protein trans-activation. Mol Cell Biol (1992) 1.24
Molecular biology and immunology of cytomegalovirus. Biochem J (1987) 1.19
The immediate early genes of human cytomegalovirus upregulate expression of the cellular genes myc and fos. Am J Respir Cell Mol Biol (1992) 1.16
A prospective study of infectious diseases following bone marrow transplantation: emergence of Aspergillus and Cytomegalovirus as the major causes of mortality. Infect Control (1983) 1.13
Coordinate enhancement of cytokine gene expression in human immunodeficiency virus type 1-infected promonocytic cells. J Virol (1990) 1.09
The immediate early genes of human cytomegalovirus require only proximal promoter elements to upregulate expression of interleukin-1 beta. Am J Respir Cell Mol Biol (1992) 0.97
Increased monokines in cytomegalovirus infected myelomonocytic cell cultures. Microb Pathog (1989) 0.96
The immediate early genes of human cytomegalovirus upregulate expression of the interleukin-2 and interleukin-2 receptor genes. Am J Respir Cell Mol Biol (1991) 0.89
Structural analysis of the major immediate early gene of human cytomegalovirus. J Virol (1984) 6.67
Temporal patterns of human cytomegalovirus transcription: mapping the viral RNAs synthesized at immediate early, early, and late times after infection. J Virol (1982) 6.20
Inflammatory and immune processes in the human lung in health and disease: evaluation by bronchoalveolar lavage. Am J Pathol (1979) 5.94
Organization and expression of the immediate early genes of human cytomegalovirus. J Virol (1983) 5.74
Idiopathic pulmonary fibrosis. N Engl J Med (2001) 5.49
Activation of the major immediate early gene of human cytomegalovirus by cis-acting elements in the promoter-regulatory sequence and by virus-specific trans-acting components. J Virol (1985) 5.47
Multiple spliced and unspliced transcripts from human cytomegalovirus immediate-early region 2 and evidence for a common initiation site within immediate-early region 1. J Virol (1985) 5.09
Promoter-regulatory region of the major immediate early gene of human cytomegalovirus. Proc Natl Acad Sci U S A (1984) 5.04
Sequence of protein synthesis in cells infected by human cytomegalovirus: early and late virus-induced polypeptides. J Virol (1978) 4.65
Identification and characterization of the human cytomegalovirus immediate-early region 2 gene that stimulates gene expression from an inducible promoter. J Virol (1987) 4.33
Temporal regulation of human cytomegalovirus transcription at immediate early and early times after infection. J Virol (1981) 4.11
Pulmonary sarcoidosis: a disorder mediated by excess helper T-lymphocyte activity at sites of disease activity. N Engl J Med (1981) 4.02
Transactivation of a human cytomegalovirus early promoter by gene products from the immediate-early gene IE2 and augmentation by IE1: mutational analysis of the viral proteins. J Virol (1990) 4.01
Cloning of the human cytomegalovirus genome as endonuclease XbaI fragments. Gene (1981) 3.63
Human cytomegalovirus contains a tegument protein that enhances transcription from promoters with upstream ATF and AP-1 cis-acting elements. J Virol (1992) 3.41
Interstitial lung disease: current concepts of pathogenesis, staging and therapy. Am J Med (1981) 3.08
Synthesis of proteins and glycoproteins in cells infected with human cytomegalovirus. J Virol (1977) 3.07
Autoregulation of the human cytomegalovirus major immediate-early gene. J Virol (1985) 2.91
Human cytomegalovirus: glycoproteins associated with virions and dense bodies. J Virol (1976) 2.80
A cis-acting element in the major immediate-early (IE) promoter of human cytomegalovirus is required for negative regulation by IE2. J Virol (1991) 2.80
A human cytomegalovirus early gene has three inducible promoters that are regulated differentially at various times after infection. J Virol (1989) 2.70
Lipopolysaccharide induces Rac1-dependent reactive oxygen species formation and coordinates tumor necrosis factor-alpha secretion through IKK regulation of NF-kappa B. J Biol Chem (2001) 2.50
Cigarette smoking and rheumatoid arthritis severity. Ann Rheum Dis (1997) 2.48
Production of fibronectin by the human alveolar macrophage: mechanism for the recruitment of fibroblasts to sites of tissue injury in interstitial lung diseases. Proc Natl Acad Sci U S A (1981) 2.34
Human alveolar macrophage growth factor for fibroblasts. Regulation and partial characterization. J Clin Invest (1982) 2.33
The promoter-regulatory region of the major immediate-early gene of human cytomegalovirus responds to T-lymphocyte stimulation and contains functional cyclic AMP-response elements. J Virol (1989) 2.32
Pulmonary involvement in the collagen vascular diseases. Am Rev Respir Dis (1979) 2.31
Human cytomegalovirus immediate-early two protein region involved in negative regulation of the major immediate-early promoter. J Virol (1990) 2.28
Participation of two human cytomegalovirus immediate early gene regions in transcriptional activation of adenovirus promoters. Virology (1987) 2.26
ATS/ERS/WASOG statement on sarcoidosis. Sarcoidosis Statement Committee. American Thoracic Society. European Respiratory Society. World Association for Sarcoidosis and Other Granulomatous Disorders. Eur Respir J (1999) 2.20
DNA of human cytomegalovirus: size heterogeneity and defectiveness resulting from serial undiluted passage. J Virol (1979) 2.16
Identification and characterization of three distinct families of glycoprotein complexes in the envelopes of human cytomegalovirus. J Virol (1988) 2.14
An in vitro system for human cytomegalovirus immediate early 2 protein (IE2)-mediated site-dependent repression of transcription and direct binding of IE2 to the major immediate early promoter. Proc Natl Acad Sci U S A (1993) 2.13
The p38 mitogen-activated protein kinase is required for NF-kappaB-dependent gene expression. The role of TATA-binding protein (TBP). J Biol Chem (1999) 2.11
Mechanisms of neutrophil accumulation in the lungs of patients with idiopathic pulmonary fibrosis. J Clin Invest (1981) 2.10
Determinants of restrictive lung function in asbestos-induced pleural fibrosis. J Appl Physiol (1985) (1990) 2.08
Maintenance of granuloma formation in pulmonary sarcoidosis by T lymphocytes within the lung. N Engl J Med (1980) 2.07
Human alveolar macrophage-derived chemotactic factor for neutrophils. Stimuli and partial characterization. J Clin Invest (1980) 2.04
Clinical role of bronchoalveolar lavage in adults with pulmonary disease. Am Rev Respir Dis (1990) 2.02
Determinants of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (1994) 2.01
Computer recognition of regional lung disease patterns. Am J Respir Crit Care Med (1999) 1.97
Cigarette smoking and lung destruction. Accumulation of neutrophils in the lungs of cigarette smokers. Am Rev Respir Dis (1983) 1.97
Immunologic reactivity of the lung: the in vivo and in vitro generation of a neutrophil chemotactic factor by alveolar macrophages. Am Rev Respir Dis (1978) 1.97
Release of interleukin-1 by alveolar macrophages of patients with active pulmonary sarcoidosis. Am Rev Respir Dis (1984) 1.96
The human cytomegalovirus IE86 protein can block cell cycle progression after inducing transition into the S phase of permissive cells. J Virol (2000) 1.92
Local allergen challenge and bronchoalveolar lavage of allergic asthmatic lungs. Description of the model and local airway inflammation. Am Rev Respir Dis (1987) 1.91
Current concepts of the pathogenesis of sarcoidosis. Am Rev Respir Dis (1987) 1.90
Lipopolysaccharide activates Akt in human alveolar macrophages resulting in nuclear accumulation and transcriptional activity of beta-catenin. J Immunol (2001) 1.85
Bronchoalveolar lavage cellularity. The distribution in normal volunteers. Am Rev Respir Dis (1992) 1.81
Coexpression of truncated human cytomegalovirus gH with the UL115 gene product or the truncated human fibroblast growth factor receptor results in transport of gH to the cell surface. Virology (1993) 1.81
Elastin fragments attract macrophage precursors to diseased sites in pulmonary emphysema. Science (1981) 1.80
Expression of a human cytomegalovirus late gene is posttranscriptionally regulated by a 3'-end-processing event occurring exclusively late after infection. Mol Cell Biol (1986) 1.78
The alveolitis of pulmonary sarcoidosis. Evaluation of natural history and alveolitis-dependent changes in lung function. Am Rev Respir Dis (1983) 1.76
Variable airway responsiveness to inhaled lipopolysaccharide. Am J Respir Crit Care Med (1999) 1.76
Localization of the immune response in sarcoidosis. Am Rev Respir Dis (1979) 1.74
Lipopolysaccharide induces prostaglandin H synthase-2 protein and mRNA in human alveolar macrophages and blood monocytes. J Clin Invest (1994) 1.74
The gene product of human cytomegalovirus open reading frame UL56 binds the pac motif and has specific nuclease activity. J Virol (1998) 1.73
Reversible oxidant-induced increases in albumin transfer across cultured endothelium: alterations in cell shape and calcium homeostasis. Blood (1985) 1.71
Lung inflammation and fibrosis. Am J Respir Crit Care Med (1998) 1.68
Bleomycin-induced interstitial pulmonary disease in the nude, athymic mouse. Am Rev Respir Dis (1979) 1.67
Pathogenesis of the granulomatous lung diseases. Am Rev Respir Dis (1984) 1.64
Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis. Eur Respir J (2002) 1.63
Regulation of human cytomegalovirus immediate-early gene expression. Intervirology (1996) 1.58
Effect of intermittent high dose parenteral corticosteroids on the alveolitis of idiopathic pulmonary fibrosis. Am Rev Respir Dis (1983) 1.56
Bronchoalveolar lavage of allergic asthmatic patients following allergen bronchoprovocation. Chest (1986) 1.53
Identification and expression of a human cytomegalovirus early glycoprotein. J Virol (1989) 1.50
Effect of a modulator deletion on transcription of the human cytomegalovirus major immediate-early genes in infected undifferentiated and differentiated cells. J Virol (1997) 1.48
Differential expression of extracellular matrix remodeling genes in a murine model of bleomycin-induced pulmonary fibrosis. Am J Pathol (1998) 1.48
The clinical utility and reliability of asbestos bodies in bronchoalveolar fluid. Am Rev Respir Dis (1991) 1.47
Both Erk and p38 kinases are necessary for cytokine gene transcription. Am J Respir Cell Mol Biol (1999) 1.47
Modulation of interleukin 1 beta gene expression by the immediate early genes of human cytomegalovirus. J Clin Invest (1990) 1.46
Rheumatoid arthritis lung disease. Determinants of radiographic and physiologic abnormalities. Arthritis Rheum (1996) 1.45
Oxidant injury of lung parenchymal cells. J Clin Invest (1981) 1.44
Induction of interleukin (IL)-8 gene expression by respiratory syncytial virus involves activation of nuclear factor (NF)-kappa B and NF-IL-6. J Infect Dis (1996) 1.44
Immunological reactivity of the lung. I. A guinea pig model for the study of pulmonary mononuclear cell subpopulations. Cell Immunol (1976) 1.43
Characterization of the inflammatory and immune effector cells in the lung parenchyma of patients with interstitial lung disease. Am Rev Respir Dis (1981) 1.42
Correlation of chest roentgenograms with pulmonary function and bronchoalveolar lavage in interstitial lung disease. Chest (1989) 1.42
Mechanisms of hypergammaglobulinemia in pulmonary sarcoidosis. Site of increased antibody production and role of T lymphocytes. J Clin Invest (1981) 1.41
High-resolution CT-derived measures of lung density are valid indexes of interstitial lung disease. J Appl Physiol (1985) (1994) 1.40
Persistence of the cytomegalovirus genome in human cells. J Virol (1979) 1.39
Regulation of the release of alveolar macrophage-derived neutrophil chemotactic factor. Am Rev Respir Dis (1980) 1.37
Synthesis of human cytomegalovirus-specified RNA and protein in interferon-treated cells at early times after infection. J Gen Virol (1982) 1.36
A multigene family encodes the human cytomegalovirus glycoprotein complex gcII (gp47-52 complex). J Virol (1988) 1.36
Guidelines for the clinical evaluation of hypersensitivity pneumonitis. Report of the Subcommittee on Hypersensitivity Pneumonitis. J Allergy Clin Immunol (1989) 1.35
Gallium-67 scanning to stage the alveolitis of sarcoidosis: correlation with clinical studies, pulmonary function studies, and bronchoalveolar lavage. Am Rev Respir Dis (1981) 1.35
Characterization of a human cytomegalovirus glycoprotein complex (gcI). J Gen Virol (1988) 1.32
Interstitial lung disease: A quantitative study using the adaptive multiple feature method. Am J Respir Crit Care Med (1999) 1.32
Low grade rhinovirus infection induces a prolonged release of IL-8 in pulmonary epithelium. J Immunol (1998) 1.31
Interferon-gamma is necessary for the expression of hypersensitivity pneumonitis. J Clin Invest (1997) 1.31
Prognostic role of eosinophils in pulmonary fibrosis. Chest (1987) 1.30
Role of interleukin-2 release by lung T-cells in active pulmonary sarcoidosis. Am Rev Respir Dis (1983) 1.30